history of glp 1 drugs Oral Small-Molecule GLP-1 Receptor Agonists: Mechanistic Insights and Emerging Therapeutic Strategies Another milestone in the evolution

In the ever-changing landscape of systemic therapies, being vigilant for potential new disease associations is a duty we all share on behalf of patients, Susan Mollan, an ophthalmologist with the University Hospitals Birmingham in the UK wrote in a related commentary

For people with straightforward health profiles who value convenience, this streamlined approach may be worth evaluating

A., Burlacu, A

They affect 20%30% of patients and usually cease during long-term therapy after a few weeks

Safety concerns come with this wider use

Endogenous GLP-1 is rapidly degraded primarily by dipeptidyl peptidase-4 (DPP-4), as well as neutral endopeptidase 24 } : CS1 maint: DOI inactive as of July 2026 (link) Journal of Diabetes